Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs

Kobe Journal of Medical Sciences

Volumn 56, Issue 3, 2010, Pages

  Mamehara, Akira ^a,b   Sugimoto, Takeshi ^a   Sugiyama, Daisuke ^a   Morinobu, SAHOKO ^a   Tsuji, Goh ^a   Kawano, Seiji ^a   Morinobu, Akio ^a   Kumagai, Shunichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kasai Municipal Hospital   (Japan)

Author keywords

Disease modifying anti rheumatic drugs; Matrix metalloproteinase 3; Radiographic progression; Rheumatoid arthritis

Indexed keywords

ACTARIT; AURANOFIN; BUCILLAMINE; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; SODIUM AUROTHIOMATE; STROMELYSIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; JOINTS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 77958568501     PISSN: 00232513     EISSN: 18830498     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Scott, DL. Grindulis, KA. Struthers, GR. Coulton, BL. Popert, AJ. Bacon, PA. 1984. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis. 43: 8-17.
2. Drossaers-Bakker, KW. de Buck, M. van Zeben, D. Zwinderman, AH. Breedveld, FC. Hazes, JM. 1999. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 42: 1854-1860.
3. Scott, DL. Symmons, DP. Coulton, BL. Popert, AJ. 1987. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1: 1108-1111.
4. Welsing, PM. van Gestel, AM. Swinkels, HL. Kiemeney, LA. van Riel, PL. 2001. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44: 2009-2017.
5. Scott, DL. Pugner, K. Kaarela, K. et al. 2000. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 39: 122-132.
6. Bathon, JM. Martin, RW. Fleischmann, RM. Tesser, JR. Schiff, MH. Keystone, EC. et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343: 1586-1593.
7. St Clair, EW. van der Heijde, D. Smolen, JS. Maini, RN. Bathon, JM. Emery, P. et al. 2004. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50: 3432-3443.
8. Klareskog, L. van der Heijde, D. de Jager, JP. Gough, A. Kalden, J. Malaise, M. et al. 2004. Theraputic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363: 675-681.
9. Takeuchi, T. Yamanaka, H. Inoue, E. Nagasawa, H. Nawata, M. Ikari, K. et al. 2008. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group Japan: one-year outcome of joint destruction(RECONFIRM-2J). Mod Rheumatol 18: 447-454.
10. Keane, J. Gershon, S. Wise, RP. et al. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104.
11. Gomez-Reino, JJ. Carmona, L. Valverde, VR. et al. 2003. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitor may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48: 2122-2127.
12. Bongartz, T. Sutton, AJ. Sweeting, MJ. et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285.
13. Mohan, N. Edwards, ET. Cupps, TR, et al. 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862-2869.
14. Smolen, JS. Kalden, JR. Scott, DL. Rozman, B. Kvien, TK. Larsen, A. Loew-Friedrich, I. Oed, C. Rosenburg, R. 1999. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353: 259-266.
15. Pullar, T. Hunter, JA. Capell, HA. 1987. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis 46:398-402.
16. Rich, E. Moreland, LW. Alarcon, GS. 1999. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol. 26:259-61.
17. Klareskog, L. Ronnelid, J. Lundberg, K. Padyukov, L. Alfredsson, L. 2008. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 26:651-675.
18. Ribbens, C. Porras, MM. Franchimont, N. Kaiser, MJ. Jasper, JM. Damas, P. Houssiau, FA. Malaise, MG. 2002. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161-166.
19. Kobayashi, A. Naito, S. Enomoto, H. Shiomoi, T. Kimura, T. Obata, K. Inoue, K. Okada, Y. 2007. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med. 131:563-570.
20. Posthumus, MD. Limburg, PC. Westra, J. Leeuwen, MA. Ruswijk, MH. 2002. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. J Rheumatol. 29:883-89.
21. Young-Min, S. Cawston, T. Marshall, N. Coady, D. Christgau, S. Saxne, T. Robins, S. Griffiths, I. 2007. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 56:3236-3247.
22. Yamanaka, H. Matsuda, Y. Tanaka, M. Sendo, W. Nakajima, H. Taniguchi, A. Kamatani, N. 2000. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis.Arthritis Reum 43:852-858.
23. Green, MJ. Gough, AKS. Devlin, J. Smith, J. Astin, P. Taylor, D. Emery, P. 2003. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 42:83-88.
24. Arnett, FC. Edworthy, SM. Bloch, DA. McShane, DJ. Fries, JF. Cooper, NS. Healey, LA. Kaplan, SR. Liang, MH. Luthra, HS. et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-324.
25. Miklus, TR. O'Dell, JR. Stoner, JA. Parrish, LA. Arend, WP. Norris, JM. Holers, VM. 2004. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 50:3776-3782.
26. van der Heijde, D. 2000. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27:261-263.
27. Syversen, SW. Goll, GL. van der Heijde, D. Landewe, R. Gaarder, PI. Odegard, S. Haavardsholm, EA. Kvien, TK. 2009. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol. 36:266-272.
28. Hashimoto, J. Garnero, P. Heijde, D. Miyasaka, N. Yamamoto, K. Kawai, S. et al. 2009. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod Rheumatol, 19:273-282.
29. Bos, WH. Bartelds, GM. Wolbink, GJ. et al. 2008. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 35:1972-1977.
30. Alessandri, C. Bombardieri, M. Papa, N. et al. 2004. Cytokine and chemokine receptor profile of peripheral blood monomuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 63:1218-1221.
31. Chen, HA. Lin, KC. Che, CH. et al. 2006. The effect of etanercept on anti-cyclic citrullinated protein antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35-39.
32. Atzeni, F. Sarzi-Putini, P. Dell' Acqua, D. et al. 2006. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8:R3.
33. Bobbio-Pallavicini, F. Caporali, R. Alpini, C. Avalle, S. Epis, OM. Klersy, C. Montecucco, C. 2007. High IgA rheumatoid factor levels are associated with poor clinical response to rumor necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis. 66:302-307.